Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy

References

• Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12(1), 20–37 (2007).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71(2 Suppl.), 517–523 (1993).
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 34(3), 433–443 (2010).
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer – shifting the paradigm. Hum. Pathol. 42(7), 918–931 (2011).
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20), 4593–4599 (1997).
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA et al.; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365(26), 2473–2483 (2011).
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J et al.; ICON7 Investigators. A Phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365(26), 2484–2496 (2011).
   PubMed Web of Science ®Google Scholar
• Huarte E, Cubillos-Ruiz JR, Nesbeth YC et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res. 68(18), 7684–7691 (2008).
   PubMed Web of Science ®Google Scholar
• Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 69(18), 7329–7337 (2009).
   PubMedGoogle Scholar
• Scarlett UK, Rutkowski MR, Rauwerdink AM et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 209(3), 495–506 (2012).
   PubMed Web of Science ®Google Scholar
• Pedroza-Gonzalez A, Xu K, Wu TC et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J. Exp. Med. 208(3), 479–490 (2011).
   PubMed Web of Science ®Google Scholar
• Marigo I, Bosio E, Solito S et al. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity 32(6), 790–802 (2010).
   PubMed Web of Science ®Google Scholar
• Conejo-Garcia JR, Benencia F, Courreges MC et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of VEGF-A. Nat. Med. 10(9), 950–958 (2004).
   PubMed Web of Science ®Google Scholar
• Conejo-Garcia JR, Buckanovich RJ, Benencia F et al. Vascular leukocytes contribute to tumor vascularization. Blood 105(2), 679–681 (2005).
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Engle X, Scarlett UK et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J. Clin. Invest. 119(8), 2231–2244 (2009).
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Fiering S, Conejo-Garcia JR. Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future Oncol. 5(8), 1189–1192 (2009).
   PubMedGoogle Scholar
• Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR. Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle 9(2), 260–268 (2010).
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J. 16(4), 348–353 (2010).
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Conejo-Garcia JR. It never rains but it pours: potential role of butyrophilins in inhibiting anti-tumor immune responses. Cell Cycle 10(3), 368–369 (2011).
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Martinez D, Scarlett UK et al. CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget 1(5), 329–338 (2010).
   PubMed Web of Science ®Google Scholar
• Nesbeth Y, Conejo-Garcia JR. Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. Clin. Dev. Immunol. 2010, 139304 (2010).
   PubMedGoogle Scholar
• Nesbeth Y, Scarlett U, Cubillos-Ruiz J et al. CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res. 69(15), 6331–6338 (2009).
   PubMed Web of Science ®Google Scholar
• Nesbeth YC, Martinez DG, Toraya S et al. CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J. Immunol. 184(10), 5654–5662 (2010).
   PubMedGoogle Scholar
• Son DS, Parl AK, Rice VM, Khabele D. Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Cancer Biol. Ther. 6(8), 1302–1312 (2007).
   PubMedGoogle Scholar
• Sangaletti S, Tripodo C, Ratti C et al. Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Cancer Res. 70(20), 7764–7775 (2010).
   PubMedGoogle Scholar
• Burke F, Relf M, Negus R, Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine 8(7), 578–585 (1996).
   PubMed Web of Science ®Google Scholar
• Fleming JS, Beaugié CR, Haviv I, Chenevix-Trench G, Tan OL. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol. Cell. Endocrinol. 247(1–2), 4–21 (2006).
   PubMed Web of Science ®Google Scholar
• Kulbe H, Chakravarty P, Leinster DA et al. Australian Ovarian Cancer Study Group. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 72(1), 66–75 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D et al.; Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203–213 (2003).
   PubMed Web of Science ®Google Scholar
• Coukos G, Conejo-Garcia JR, Roden RB, Wu TC. Immunotherapy for gynaecological malignancies. Expert Opin. Biol. Ther. 5(9), 1193–1210 (2005).
   PubMed Web of Science ®Google Scholar
• Conejo-Garcia JR, Benencia F, Courreges MC et al. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28-antitumor T cells. Cancer Res. 64(6), 2175–2182 (2004).
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104(9), 3360–3365 (2007).
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T-cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102(51), 18538–18543 (2005).
   PubMed Web of Science ®Google Scholar
• Kryczek I, Banerjee M, Cheng P et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114(6), 1141–1149 (2009).
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942–949 (2004).
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Gnjatic S, Sabbatini P et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin. Cancer Res. 14(9), 2740–2748 (2008).
   PubMedGoogle Scholar
• Sabbatini PJ, Ragupathi G, Hood C et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin. Cancer Res. 13(14), 4170–4177 (2007).
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol. Cancer Ther. 11(3), 517–525 (2012).
   PubMed Web of Science ®Google Scholar
• Carpenito C, Milone MC, Hassan R et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106(9), 3360–3365 (2009).
   PubMed Web of Science ®Google Scholar
• Tchou J, Wang LC, Selven B et al. Mesothelin, a novel immunotherapy target for triple-negative breast cancer. Breast Cancer Res. Treat. 133(2), 799–804 (2012).
   PubMed Web of Science ®Google Scholar
• Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J. Exp. Med. 209(2), 201–209 (2012).
   PubMed Web of Science ®Google Scholar
• Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024), 1612–1616 (2011).
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Piantadosi S et al.; NABTT CNS Consortium. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res. 16(8), 2443–2449 (2010).
   PubMed Web of Science ®Google Scholar
• Ahonen CL, Wasiuk A, Fuse S et al. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 111(6), 3116–3125 (2008).
   PubMed Web of Science ®Google Scholar
• Ahonen CL, Doxsee CL, McGurran SM et al. Combined TLR and CD40 triggering induces potent CD8+ T-cell expansion with variable dependence on type I IFN. J. Exp. Med. 199(6), 775–784 (2004).
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Baird JR, Tesone AJ et al. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res. 72(7), 1683–1693 (2012).
   PubMed Web of Science ®Google Scholar
• Nick AM, Stone RL, Armaiz-Pena G et al. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J. Natl Cancer Inst. 103(21), 1596–1612 (2011).
   PubMedGoogle Scholar
• Buckanovich RJ, Facciabene A, Kim S et al. Endothelin B receptor mediates the endothelial barrier to T-cell homing to tumors and disables immune therapy. Nat. Med. 14(1), 28–36 (2008).
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11(10), 702–711 (2011).
   PubMed Web of Science ®Google Scholar
• Kraman M, Bambrough PJ, Arnold JN et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science 330(6005), 827–830 (2010).
   PubMed Web of Science ®Google Scholar